Immuneering to Present at the Jefferies Healthcare Conference
30 Maio 2023 - 9:00AM
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology
company developing medicines for broad populations of cancer
patients with an initial aim to develop a universal-RAS therapy,
today announced that management will present at the Jefferies
Healthcare Conference to discuss the company’s pipeline, platform,
and business strategy. Participating will be Ben Zeskind, Ph.D.,
Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief
Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and
Mallory Morales, CPA, Vice President of Finance, Treasurer.
Format: Company Presentation and 1x1 Investor
MeetingsPresentation: June 8 from 10:00 – 10:25 am ET in Track
2
The presentations will be webcast live and
archived in the Investor Relations section of Immuneering’s website
at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company
developing medicines for broad populations of cancer patients with
an initial aim to develop a universal-RAS therapy. The company aims
to achieve universal activity through deep cyclic inhibition of the
MAPK pathway, impacting cancer cells while sparing healthy cells.
Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a
study in patients with advanced solid tumors harboring RAS
mutations. The company’s development pipeline also includes
IMM-6-415, a universal-MAPK program, as well as several early-stage
programs. For more information, please visit
www.immuneering.com.
Media Contact:Gina Nugent Nugent
Communications 617-460-3579 gina@nugentcommunications.com
Investor Contacts: Laurence
Watts Gilmartin
Group 619-916-7620 laurence@gilmartinir.com
or
Kiki Patel, PharmD Gilmartin
Group 332-895-3225kiki@gilmartinir.com
Immuneering (NASDAQ:IMRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Immuneering (NASDAQ:IMRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024